US Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a Potential 210% Upside in the Biotech Sector

Vir Biotechnology, Inc. (NASDAQ: VIR) is capturing attention in the biotech investment arena with its compelling potential upside of 210.33%, as indicated by analyst ratings. This clinical-stage biopharmaceutical company, headquartered..

RxSight, Inc. (RXST) Stock Analysis: A Look at the 53.93% Potential Upside and Analyst Consensus

RxSight, Inc. (NASDAQ: RXST), a commercial-stage medical technology company, is making waves in the healthcare sector with its innovative approach to cataract surgery. Specializing in the development and sale of..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 60% Potential Upside in the Pediatric Orthopedic Sector

OrthoPediatrics Corp. (NASDAQ: KIDS) stands out in the healthcare sector, specifically within the medical devices industry, as a company focused on the unique needs of pediatric orthopedic patients. With a..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Growth in a Complex Market

For investors with a keen eye on the healthcare sector, Sonida Senior Living, Inc. (SNDA) represents a compelling opportunity in the niche of senior housing. Based in Dallas, Texas, the..

Opthea Limited (OPT)

⚠️ No article content returned.

..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Healthcare Innovator with 93% Upside Potential

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a dynamic player in the healthcare sector specializing in treatments for rare diseases, presents a tantalizing opportunity for investors seeking high-growth potential. With its market..

Celcuity Inc. (CELC) Stock Analysis: A Promising Biotech with Over 100% Potential Upside

Individual investors eyeing opportunities in the biotechnology sector may find Celcuity Inc. (NASDAQ: CELC) an intriguing prospect. This Minneapolis-based company, with a market capitalization of $532.02 million, is on a..

Simulations Plus, Inc. (SLP) Stock Analysis: A 93% Potential Upside Awaits Investors

Simulations Plus, Inc. (NASDAQ: SLP), a leader in the healthcare sector, specifically within the health information services industry, offers an intriguing investment opportunity highlighted by a notable 93.09% potential upside,..

Day One Biopharmaceuticals (DAWN) Stock Analysis: Is a 264% Upside Within Reach?

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is capturing investor attention with its ambitious goal of transforming the treatment landscape for childhood and adult diseases through innovative biotechnology solutions. The company’s..

Evolus, Inc. (EOLS) Stock Analysis: Unpacking the 144% Potential Upside in the Aesthetic Market

Evolus, Inc. (NASDAQ: EOLS) stands at a fascinating intersection of opportunity and potential within the healthcare sector. Specializing in the aesthetic market, this Newport Beach-based company is gaining traction with..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Unveiling a 170% Potential Upside

Trevi Therapeutics, Inc. (NASDAQ: TRVI) stands out in the volatile biotechnology sector, capturing the attention of investors with a staggering potential upside of 170.69%. This clinical-stage biopharmaceutical company is making..

Cronos Group Inc. (CRON) Stock Analysis: Unpacking the 27.6% Revenue Growth in a Competitive Cannabis Market

Investors eyeing opportunities in the cannabis sector should consider the recent performance and future potential of Cronos Group Inc. (NASDAQ: CRON). This Canadian-based company, with a market cap of $798.97..

Personalis, Inc. (PSNL) Stock Analysis: Navigating Growth in Cancer Genomics with a 6.45% Potential Upside

Personalis, Inc. (NASDAQ: PSNL) stands at the frontier of the burgeoning cancer genomics sector, offering investors a unique opportunity to tap into a rapidly evolving market. Headquartered in Fremont, California,..

COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a Potential 263% Upside in the Mental Health Sector

COMPASS Pathways Plc (NASDAQ: CMPS) is making waves in the healthcare sector, focusing on the burgeoning field of mental health treatment. With a market capitalization of $408.87 million, this UK-based..

Arvinas, Inc. (ARVN) Stock Analysis: Exploring a Potential 145% Upside in Biotech Innovation

Arvinas, Inc. (NASDAQ: ARVN) is making waves in the biotechnology sector with its innovative approach to treating challenging diseases through protein degradation. With a market capitalization of $575.9 million, this..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Potential 171% Upside in the Biotech Sector

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a burgeoning player in the biotechnology industry, focusing on the development and commercialization of drugs targeting organ fibrosis, a condition that affects millions globally...

Tourmaline Bio, Inc. (TRML) Stock Analysis: A 197% Upside with Strong Buy Ratings

Investors searching for promising opportunities in the biotechnology sector might turn their attention to Tourmaline Bio, Inc. (NASDAQ: TRML), a clinical-stage biotech firm making strides in the development of transformative..

Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Stock with Over 55% Potential Upside

Investors with a keen interest in the biotechnology sector might find Cogent Biosciences, Inc. (NASDAQ: COGT) a compelling prospect. Headquartered in Waltham, Massachusetts, Cogent Biosciences focuses on developing precision therapies..

Delcath Systems, Inc. (DCTH): Investor Outlook and Potential 111% Upside

Delcath Systems, Inc. (NASDAQ: DCTH) is capturing the attention of investors with its promising potential upside of 111.21%, as indicated by recent analyst ratings. Operating within the healthcare sector, Delcath..

Savara, Inc. (SVRA) Stock Analysis: Exploring 176.96% Potential Upside in the Biotech Sector

Savara, Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its focus on rare respiratory diseases. Headquartered in Langhorne, Pennsylvania, Savara’s dedicated efforts towards..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds